Source: DGNews  |  Posted 9 years ago

By Charlene Laino

SAN ANTONIO, TX -- December 12, 2002 -- Updated results from the ongoing Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial continue to suggest that anastrozole is superior to tamoxifen in the treatment of postmenopausal women with early-stage breast cancer.

Principal United States Investigator Aman Buzdar, MD, a professor in the Department of Breast Medical Oncology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, United States, presented the data here on December 11th at the 25th Annual San Antonio Breast Cancer Symposium (SABCS).

The results of the ATAC trial main analysis were reported in full at last year's SABCS. That analysis showed that at a median follow-up of 33.3 months, 89.4 percent of women given anastrozole were disease free, compared with 87.4 percent of women given tamoxifen -- an absolute difference of 2.0 percent.

On the basis of that analysis, the U. S. Food and Drug Administration approved anastrozole (Arimidex